Immune signature to predict trastuzumab benefit: Potential and pitfalls

Journal of Clinical Oncology

Volumn 33, Issue 31, 2015, Pages 3671-3672

  Gavin, Patrick G ^a   Song, Nan ^a   Kim, S Rim ^a   Pogue Geile, Katherine L ^a   Paik, Soonmyung ^a  

^a NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TUMOR MARKER;

CANCER CHEMOTHERAPY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; LETTER; PREDICTION; PRIORITY JOURNAL; BREAST TUMOR; FEMALE; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2;

EID: 84947293268     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.9650     Document Type: Letter

References (3)

1. Perez EA, Thompson EA, Ballman KV, et al: Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial. J Clin Oncol 33:701-708, 2015
2. Simon R, Radmacher MD, Dobbin K, et al: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95:14-18, 2003
3. Pogue-Geile KL, Kim C, Jeong JH: Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst 105:1782-1788, 2013